VAR2 Pharma’s executive chairman and UBC professor Dr. Mads Daugaard has been awarded a 5-year grant from the CIHR to explore how chondroitin sulfate molecules are regulated during cancer progression. The result of this research project may help inform how best to deploy VAR2 Pharma’s therapeutics in solid tumor indications.
